Skip to main content
. Author manuscript; available in PMC: 2021 Oct 25.
Published in final edited form as: ACS Nano. 2020 May 1;14(6):6519–6531. doi: 10.1021/acsnano.9b08216

Figure 4.

Figure 4.

Antiatherogenic effect of CSNP. (A) Schematic of experimental plan for antiatherogenic therapy. Doses per injection were 15 mg/kg ST and 100 mg/kg CD for CSNP group, 400 mg/kg CD for CD group, and 15 mg/kg ST for ST and LP-ST groups. (B) Representative bright field images of dissected carotid arteries. The arrows indicate where cross-sectional images were obtained. (C) Quantification of lesion areas in panel B. (D) Representative histological images of the LCA sections after Oil-Red-O staining. The scale bar indicates 200 μm. (E) Quantification of plaque area in panel D. (F) Quantification of macrophage area in the LCA sections after CD68 staining. (G) Plasma cholesterol level. (H) Body weight during treatment. Data are mean ± s.e.m. [n = 5 (LP-ST) or 7 (PBS, CD, ST, and CSNP) for C, E, F, and G; n = 5 for H; NS, not significant; *P < 0.05, ***P < 0.001, one-way ANOVA and Tukey’s multiple comparison test].